- Wolters Kluwer shares climbed nearly 4% in Amsterdam trading following the upgrade.
- J.P. Morgan upgraded to Overweight from Neutral and raised its price target to €87 from €73.
- The upgrade was driven by compelling valuation and signs that artificial intelligence will accelerate growth in Wolters Kluwer's core businesses.
- Analyst Daniel Kerven noted that the upgrade reflects growing confidence in Wolters Kluwer's investments and acquisitions, particularly in AI products.
- J.P. Morgan lowered its weighted average cost of capital (WACC) assumptions for several divisions and raised its terminal growth rate, contributing to the price target increase.
- The new target implies a 2027 price-to-earnings multiple of 12.9 times, which is still a 20% discount to peer Pearson.
- Kerven highlighted that the stock trades at 9 times 2027 estimated earnings, a 40% discount to RELX and a 60% discount to U.S. peers.
- He also pointed to potential private equity interest, estimating a leveraged buyout could generate a base case internal rate of return of 17%.
- Recent acquisitions, including Libra and Brightflag, have accelerated the company’s AI roadmap.
- Despite the upgrade, J.P. Morgan remains negative on the company’s UpToDate clinical information unit, predicting its organic growth will turn negative within five years.
- Kerven stated this was likely the first real WK upgrade for 18 months, as consensus price targets are only now catching up to risks reflected in the shares.
Wolters Kluwer's stock jumped nearly 4% in Amsterdam trading after J.P. Morgan upgraded its rating from Neutral to Overweight and raised the price target from €73 to €87. Analyst Daniel Kerven noted that this upgrade reflects a growing confidence in the company's investments and AI initiatives.24
The upgrade was influenced by lowered weighted average cost of capital (WACC) assumptions for its Legal, Tax, and Financial & Corporate Compliance divisions, alongside a raised terminal growth rate. These adjustments, combined with a modest currency tailwind, contributed to the price target increase.
Kerven highlighted that the new target implies a 2027 price-to-earnings multiple of 12.9 times, which remains a 20% discount to peer Pearson. The stock currently trades at 9 times 2027 estimated earnings, a 40% discount to RELX and a 60% discount to U.S. peers.67
The analyst also pointed to potential private equity interest, estimating that a leveraged buyout could yield a base case internal rate of return of 17%, with upside to 23% if certain assets, like the Tax division, were sold at premium multiples.8
Despite the positive outlook, J.P. Morgan remains cautious about the UpToDate clinical information unit, predicting its organic growth may turn negative within five years due to competition from AI-native rivals. However, the unit is still valued at approximately €2.6 billion, reflecting years of expected positive cash flow.10
Kerven remarked that this upgrade is likely the first significant one for Wolters Kluwer in 18 months, as consensus price targets are only now aligning with risks already reflected in the shares, which have fallen over 55% in the past year.
“Analyst Daniel Kerven noted that the upgrade reflects growing confidence in Wolters Kluwer's AI investments, which have strengthened its 'AI moat.' Despite this positive outlook, J.P. Morgan remains negative on the company's UpToDate unit, predicting its organic growth could turn negative within five years.”
